<DOC>
	<DOCNO>NCT01428765</DOCNO>
	<brief_summary>This study constitute Phase I Registry Program . The main objective study characterize newly diagnose non-valvular AF patient population risk stroke selection antithrombotic treatment stroke prevention real-world set dabigatran etexilate approve prevention stroke systemic emboli patient non-valvular AF different region world .</brief_summary>
	<brief_title>GLORIA-AF Registry Program ( Phase I )</brief_title>
	<detailed_description>Study Design : cross-sectional</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Inclusion criterion : 1 ) Patients newly diagnose nonvalvular atrial fibrillation risk stroke . Exclusion criterion : 1 . Presence mechanical heart valve , valve disease expect require valve replacement intervention ; 2 . Patients receive 60 day oral anticoagulant treatment ( vitamin K antagonist ) ( VKA ) lifetime ; 3 . Atrial fibrillation ( AF ) generally reversible cause ; 4 . Patients medical condition atrial fibrillation chronic use oral anticoagulant ( VKAs ) indicate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>